Sensitive and Portable Physician Office-Based Urine Analyzer to Tackle Prescription Drug Abuse

灵敏的便携式医生办公室尿液分析仪可解决处方药滥用问题

基本信息

  • 批准号:
    9256099
  • 负责人:
  • 金额:
    $ 22.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-03-01 至 2018-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The United States is in the midst of a prescription opioid epidemic. Deaths from misuse (51 daily) exceed deaths from heroin overdose and account for nearly one-fifth of all drug-related deaths. The estimated burden on the US healthcare system was $9.5 billion in 2005 and increased to an estimated $72.5 billion annually in 2014. A key recommendation of several federal agencies is to use urine drug testing (UDT) before prescribing opioids to establish overdosing (above expected levels of opioids in urine) or misuse with intent to resell (low or absent opioids despite patient claims to the contrary). Current strategy for UDT involves a qualitative screening immunoassay, followed by quantification using HPLC or GC/MS for positive cases. Screening immunoassays use benchtop analyzers that require experienced personnel, time, and a laboratory setup. Physicians who do not have access to in-house testing have to send out patient samples for screening. Thus, laboratory testing of every patient suffering from chronic pain at every visit imposes unacceptable delays to treatment and is not followed by most physicians. A quick, affordable, layman operable, point of care UDT in the physician's office will help in rapid diagnosis of problems and potentially halt the epidemic. BreviTest Technologies has developed a low-cost, portable analyzer to perform a rapid, quantitative ELISA test within a 10-minute run time. The sample is loaded into a cartridge that is placed in the analyzer, and a robotic mechanism controls the movement of antibody-conjugated magnetic nanoparticles through successive fluid wells, where enhanced mixing patterns substantially reduce the time required for each ELISA step. This innovative approach enables the implementation of a rapid, portable, fully automated ELISA test with accuracy comparable to a standard laboratory ELISA. In this SBIR Phase I project, BreviTest will develop and optimize an ELISA test for opioids in urine using the BreviTest robotic analyzer. The Specific Aims for the project are: (1) Develop a competitive ELISA for opioids using the BreviTest analyzer platform. We will determine the optimal reagent concentrations for the immunoassay and characterize performance of the assay in the BreviTest platform. Performance parameters will include dynamic range, repeatability, and limit of quantification. (2) Perform a limited proof-of- concept field study of the analyzer on de-identified urine samples in collaboration with a local pathology laboratory. BreviTest offers a unique platform to create an ELISA test for performing rapid quantifications of urine drug levels at the physician's office, which will be an invaluable tool to render more effective dosing to patients, paving the way towards lower toxicity and a better quality of life.
项目摘要 美国正处于处方阿片类药物的流行之中。滥用造成的死亡(每天51人)超过 海洛因过量致死人数最多,占所有与毒品有关的死亡人数的近五分之一。估计负担 2005年,美国医疗保健系统的支出为95亿美元,2005年估计增加到每年725亿美元。 2014.几个联邦机构的一个关键建议是在开处方前使用尿液药物检测(UDT 阿片类药物,以确定过量(尿液中阿片类药物的预期水平以上)或滥用意图转售(低或 不存在阿片类药物,尽管患者声称相反)。UDT的当前策略涉及定性筛查 对于阳性病例,随后使用HPLC或GC/MS进行定量。筛选免疫测定 使用需要有经验的人员、时间和实验室设置的台式分析仪。医生们 无法获得内部检测的患者必须将患者样本送去筛查。因此, 在每次就诊时,患有慢性疼痛的每个患者都会对治疗造成不可接受的延迟, 其次是大多数医生。在医生办公室快速、经济实惠、外行可操作的护理点UDT 将有助于快速诊断问题,并有可能阻止流行病。BreviTest Technologies已 开发了一种低成本的便携式分析仪,可在10分钟的运行时间内进行快速定量ELISA检测。 样品被装载到放置在分析仪中的盒中,并且机器人机构控制分析仪的操作。 抗体缀合的磁性纳米颗粒通过连续的流体威尔斯孔的运动,其中增强了 混合模式实质上减少了每个ELISA步骤所需的时间。这种创新的方法使 实现快速、便携、全自动ELISA检测,其准确度可与标准品相媲美 实验室ELISA在SBIR第一阶段项目中,BreviTest将开发和优化阿片类药物的ELISA检测, 使用BreviTest机器人分析仪检测尿液。本项目的具体目标是:(1)开发具有竞争力的 使用BreviTest分析仪平台进行阿片类药物的ELISA。我们将确定最佳试剂浓度 用于免疫测定并表征BreviTest平台中测定的性能。性能 参数包括动态范围、重复性和定量限。(2)执行有限的证明- 与当地病理学合作,对分析仪进行去识别尿液样本的概念性现场研究 实验室BreviTest提供了一个独特的平台来创建一个ELISA测试,用于快速定量 医生办公室的尿液药物水平,这将是提供更有效给药的宝贵工具 患者,为降低毒性和提高生活质量铺平了道路。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(6)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL JOHN HEFFERNAN其他文献

MICHAEL JOHN HEFFERNAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL JOHN HEFFERNAN', 18)}}的其他基金

Bedside right-heart catheterization for early diagnosis and more effective management of patients with heart failure and primary pulmonary hypertension
床边右心导管检查可对心力衰竭和原发性肺动脉高压患者进行早期诊断和更有效的治疗
  • 批准号:
    10696663
  • 财政年份:
    2023
  • 资助金额:
    $ 22.44万
  • 项目类别:
Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery
子宫壁膜锚定装置用于预防胎儿镜手术后子宫膜过早破裂
  • 批准号:
    10301644
  • 财政年份:
    2021
  • 资助金额:
    $ 22.44万
  • 项目类别:
Southwest National Pediatric Device Consortium
西南国家儿科设备联盟
  • 批准号:
    10466837
  • 财政年份:
    2018
  • 资助金额:
    $ 22.44万
  • 项目类别:
Southwest National Pediatric Device Consortium
西南国家儿科设备联盟
  • 批准号:
    10468511
  • 财政年份:
    2018
  • 资助金额:
    $ 22.44万
  • 项目类别:
Southwest National Pediatric Device Consortium
西南国家儿科设备联盟
  • 批准号:
    10247488
  • 财政年份:
    2018
  • 资助金额:
    $ 22.44万
  • 项目类别:
Southwest National Pediatric Device Consortium
西南国家儿科设备联盟
  • 批准号:
    10683882
  • 财政年份:
    2018
  • 资助金额:
    $ 22.44万
  • 项目类别:
Southwest National Pediatric Device Consortium
西南国家儿科设备联盟
  • 批准号:
    9768952
  • 财政年份:
    2018
  • 资助金额:
    $ 22.44万
  • 项目类别:
Sensitive and Portable Physician Office-Based Urine Analyzer to Tackle Prescription Drug Abuse
灵敏的便携式医生办公室尿液分析仪可解决处方药滥用问题
  • 批准号:
    9884752
  • 财政年份:
    2017
  • 资助金额:
    $ 22.44万
  • 项目类别:
Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery
子宫壁膜锚定装置用于预防胎儿镜手术后子宫膜过早破裂
  • 批准号:
    9981774
  • 财政年份:
    2017
  • 资助金额:
    $ 22.44万
  • 项目类别:
Curbside Immunoassay Device for Quantitative Measurement of Cannabis Intoxication
用于定量测量大麻中毒的路边免疫测定装置
  • 批准号:
    9141902
  • 财政年份:
    2016
  • 资助金额:
    $ 22.44万
  • 项目类别:

相似国自然基金

湍流和化学交互作用对H2-Air-H2O微混燃烧中NO生成的影响研究
  • 批准号:
    51976048
  • 批准年份:
    2019
  • 资助金额:
    61.0 万元
  • 项目类别:
    面上项目

相似海外基金

COMPAS: co integration of microelectronics and photonics for air and water sensors
COMPAS:微电子学和光子学的共同集成,用于空气和水传感器
  • 批准号:
    10108154
  • 财政年份:
    2024
  • 资助金额:
    $ 22.44万
  • 项目类别:
    EU-Funded
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Standard Grant
SBIR Phase I: High-Efficiency Liquid Desiccant Regenerator for Desiccant Enhanced Evaporative Air Conditioning
SBIR 第一阶段:用于干燥剂增强蒸发空调的高效液体干燥剂再生器
  • 批准号:
    2335500
  • 财政年份:
    2024
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Standard Grant
Catalyzing Sustainable Air Travel: Unveiling Consumer Willingness to Pay for Sustainable Aviation Fuel through Information Treatment in Choice Experiment and Cross-Country Analysis
促进可持续航空旅行:通过选择实验和跨国分析中的信息处理揭示消费者支付可持续航空燃油的意愿
  • 批准号:
    24K16365
  • 财政年份:
    2024
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Phenotypic and lineage diversification after key innovation(s): multiple evolutionary pathways to air-breathing in labyrinth fishes and their allies
合作研究:关键创新后的表型和谱系多样化:迷宫鱼及其盟友呼吸空气的多种进化途径
  • 批准号:
    2333683
  • 财政年份:
    2024
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Continuing Grant
Collaborative Research: Phenotypic and lineage diversification after key innovation(s): multiple evolutionary pathways to air-breathing in labyrinth fishes and their allies
合作研究:关键创新后的表型和谱系多样化:迷宫鱼及其盟友呼吸空气的多种进化途径
  • 批准号:
    2333684
  • 财政年份:
    2024
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Continuing Grant
CRII: CSR: Towards an Edge-enabled Software-Defined Vehicle Framework for Dynamic Over-the-Air Updates
CRII:CSR:迈向支持边缘的软件定义车辆框架,用于动态无线更新
  • 批准号:
    2348151
  • 财政年份:
    2024
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Standard Grant
Smoldering coarse woody debris and air quality
阴燃粗木质碎片和空气质量
  • 批准号:
    IM240100016
  • 财政年份:
    2024
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Mid-Career Industry Fellowships
Simulating Urban Air Pollution In The Lab
在实验室模拟城市空气污染
  • 批准号:
    MR/Y020014/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Fellowship
Development of a low-pressure loss air purification device using rotating porous media and a proposal for its use in ventilation systems
使用旋转多孔介质的低压损失空气净化装置的开发及其在通风系统中的使用建议
  • 批准号:
    24K17404
  • 财政年份:
    2024
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了